Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: a subgroup analysis of ENGOT-OV60/GOG-3052/ RAMP 201 part A
Authors
Banerjee, S.Van Nieuwenhuysen, E.
Santin, A.
Ring, K.
Colombo, N.
Thaker, P.
Prendergast, E.
Clamp, Andrew
Ray-Coquard, I.
Chon, H. S.
Moore, K.
Salinas, E.
Rose, P.
O'Malley, D.
Oaknin, A.
Monk, B.
Holloway, R.
Newman, G.
Moroney, J.
Van Gorp, T.
Kalbacher, E.
Gennigens, C.
Wojtynek, N.
Lustgarten, S.
Grisham, R.
Affiliation
The Christie NHS Foundation Trust and University of Manchester, NCRI, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Banerjee S, Van Nieuwenhuysen E, Santin A, Ring K, Colombo N, Thaker P, et al. Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/ RAMP 201 Part A. GYNECOLOGIC ONCOLOGY. 2024 NOV;190:S55-S6. PubMed PMID: WOS:001330731400075. English.Journal
Gynecologic OncologyDOI
10.1016/j.ygyno.2024.07.084Additional Links
https://dx.doi.org/10.1016/j.ygyno.2024.07.084Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ygyno.2024.07.084